Empire Life Investments’s ARS Pharmaceuticals SPRY Stock Holding History

Empire Life Investments’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.78M	Sell	471,856 -27,294	-5%	-$235K	0.21%	76
2026 Q1	$4.05M	Buy	499,150 +146,548	+42%	+$1.4M	0.25%	72
2025 Q4	$4.11M	Sell	352,602 -3,084	-0.9%	-$30K	0.23%	75
2025 Q3	$3.57M	Buy	+355,686	New	+$5.1M	0.21%	80

Other funds holding SPRY

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

FWP

FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

NFGCM

Norman Fields Gottscho Capital Management New York $330M AUM 27.75% 1-Year Est. Return

EWM

Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

BAM

Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Empire Life Investments's SPRY Position: Q2 2026 in Review

Empire Life Investments reduced its ARS Pharmaceuticals (SPRY) stake by 5.5% in Q2 2026, selling an estimated $235K and leaving 471,856 shares worth $3.78M. The position accounts for 0.21% of the portfolio, ranked #76.

Empire Life Investments first reported a position in SPRY in Q3 2025 and has held it in 4 quarters since. The position peaked at $4.11M in Q4 2025. 33 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

Empire Life Investments held 471,856 shares of ARS Pharmaceuticals worth $3.78M as of Q2 2026.
Empire Life Investments sold 27,294 ARS Pharmaceuticals shares in Q2 2026, an estimated $235K.
ARS Pharmaceuticals made up 0.21% of Empire Life Investments's portfolio in Q2 2026, its #76 holding.
Empire Life Investments first reported a position in ARS Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
Empire Life Investments's ARS Pharmaceuticals position peaked at $4.11M in Q4 2025.
33 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Empire Life Investments's 13F filing for Q2 2026, filed 24 Jul 2026.